Chembio Diagnostics Inc (CEMI, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Chembio Diagnostics Inc develops, manufactures, and commercializes point of care diagnostic tests that detect infectious diseases. Its products are rapid tests for the detection of HIV 1/2 antibodies, and for the detection of HIV and Syphilis antibodies. Chembio Diagnostics Inc has a market cap of $100.889 million; its shares were traded at around $5.87 with and P/S ratio of 2.52.
For the last quarter Chembio Diagnostics Inc reported a revenue of $7.60 million, compared with the revenue of $5.99 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $33.4 million, an increase of 39.1% from last year. For the last five years Chembio Diagnostics Inc had an average revenue decline of 0.3% a year.
The reported loss per diluted share was 55 cents for the year, compared with the loss per share of $0.25 in the previous year. The Chembio Diagnostics Inc had an operating margin of -22.88%, compared with the operating margin of -27% a year before. The 10-year historical median operating margin of Chembio Diagnostics Inc is -1.66%. The profitability rank of the company is 2 (out of 10).
At the end of the fiscal year, Chembio Diagnostics Inc has the cash and cash equivalents of $12.5 million, compared with $3.79 million in the previous year. The long term debt was $0.17 million, compared with $0.10 million in the previous year. Chembio Diagnostics Inc has a financial strength rank of 8 (out of 10).
At the current stock price of $5.87, Chembio Diagnostics Inc is traded at 60.8% premium to its historical median P/S valuation band of $3.65. The P/S ratio of the stock is 2.52, while the historical median P/S ratio is 1.57. The stock lost 23.27% during the past 12 months.
For the complete 20-year historical financial data of CEMI, click here.
